Italian Real-Life Experience on the Use of Mogamulizumab in Patients with Cutaneous T-Cell Lymphomas.

Mycosis fungoides and Sèzary syndrome are the most studied subtypes common cutaneous T-cell lymphomas. The current treatment objective is to improve the clinical manifestations of the disease in the affected areas, to relieve symptoms and to halt disease progression. Patients with early-stage mycosis fungoides are usually managed with skin-directed therapies, whereas patients with resistant or advanced-stage mycosis fungoides or Sèzary syndrome often require systemic drugs. Over the last decade, new drugs have been developed, increasing the breadth of treatment options for cutaneous T-cell lymphomas patients. Mogamulizumab is a first-in-class defucosylated humanized IgG1 κ monoclonal antibody, which exerts its anti-tumour action by selectively binding to C-C chemokine receptor 4 and increasing antibody-dependent cellular cytotoxicity activity against malignant T-cells. Several clinical trials showed that mogamulizumab is able to effectively control the cutaneous T-cell lymphomas in each site (skin, blood, lymph nodes and viscera), improving patients' symptoms, function and overall quality of life with a manageable safety profile. In this report, we discuss 12 cases of patients with mycosis fungoides or Sèzary syndrome successfully treated with mogamulizumab in real-life clinical practice in Italy.

Informations de copyright

© 2022 Caruso et al.

Déclaration de conflit d'intérêts

Pier Luigi Zinzani received consultant fees from MSD, Eusapharma and Novartis; speaker fees from Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therap, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, Incyte and Beigene; Advisory Board fees from Secura-Bio, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, TG Therap, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, ADC Therapy, Incyte and Beigene. Pietro Quaglino received speaker and advisory board fees from Kyowa Kirin, Takeda, Therakos Cellgene, Helsinn, Recordati, 4 SC. Cesare Massone received speaker and advisory board fees from Kyowa Kirin, Takeda. The other authors report no conflicts of interest in this work.